Abstract
The pharmaceutical
industry, as a high-input, high-risk, and high-return sector, is closely
related to human life and health. With the continuous refinement of the global
division of labor, the global value chain system of the pharmaceutical
manufacturing industry is constantly being perfected, and the government's
investment in health is also increasing. This paper uses databases such as UIBE
and GHED from 2000 to 2018 to calculate the degree of embeddedness in the
global value chain of the pharmaceutical manufacturing industry in 64 countries
and empirically tests the internal mechanism by which government health
expenditure affects this embeddedness. The study finds that government health
expenditure has a "U"-shaped non-linear relationship with the
embeddedness of the pharmaceutical manufacturing industry in the global value
chain of the home country. The mediating effect shows that government health
expenditure can influence the intensity of intellectual property protection,
which in turn affects the embeddedness of the pharmaceutical manufacturing
industry in the global value chain. Furthermore, the study finds that
government health expenditure also has a "U"-shaped non-linear
relationship with the strength of intellectual property protection in the
pharmaceutical manufacturing industry, and that the intensity of intellectual
property protection has a positive impact on its embeddedness in the global
value chain.
Keywords: Pharmaceutical Manufacturing, Global Value Chain, Intellectual
Property Protection, Government Expenditure.